The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States.
J Med Econ
; 25(1): 755-761, 2022.
Article
en En
| MEDLINE
| ID: mdl-35611840
Type 1 Gaucher disease (GD1) is a rare inherited condition. Long-term enzyme replacement therapy (ERT) can reverse and prevent complications. Imiglucerase, taliglucerase alfa, and velaglucerase alfa are 3 ERTs used to treat GD1. In this study, we estimated how increasing uptake of velaglucerase alfa vs. the other ERTs would impact the budget of a hypothetical US healthcare plan. The results show that increased uptake of velaglucerase alfa is cost-saving for US health plans.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad de Gaucher
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
J Med Econ
Asunto de la revista:
SERVICOS DE SAUDE
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos